enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Up 100.0% in February

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 200 shares, a growth of 100.0% from the February 13th total of 100 shares. Based on an average daily volume of 9,200 shares, the short-interest ratio is currently 0.0 days.

enGene Price Performance

enGene stock opened at $0.69 on Friday. The firm has a fifty day simple moving average of $0.87 and a two-hundred day simple moving average of $1.25. enGene has a twelve month low of $0.42 and a twelve month high of $6.50.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.